Chest
Original ResearchAn Open-Label Trial of Granulocyte Macrophage Colony Stimulating Factor Therapy for Moderate Symptomatic Pulmonary Alveolar Proteinosis
Section snippets
Materials and Methods
The study was a prospective, open-label clinical trial of daily GM-CSF therapy in a group of patients with idiopathic PAP. The study was approved by the Institutional Review Board at the Cleveland Clinic Foundation, and informed consent was obtained from all patients prior to enrollment. A diagnosis of idiopathic PAP was confirmed by transbronchial lung biopsy (n = 8) or open-lung biopsy (n = 17) in all patients. All patients had pretreatment serum assayed for GM-CSF–neutralizing antibody as
Dosage and Dose Escalation
Patients were treated with recombinant human yeast-derived GM-CSF (Leukine; formerly Immunex Corporation and now Berlex; Seattle, WA) administered subcutaneously once daily for 3 months. Patients were trained to self-administer daily subcutaneous therapy. The starting dose was 250 μg/d, which was progressively increased to 5 μg/kg/d for the second month of study, and to 9 μg/kg/d for the third month. After the patient received therapy for 3 months, if the clinical response was still suboptimal
Monitoring During Therapy
The first dose was administered in the clinic, and patients were observed for 2 h. Injection sites were rotated between the anterior abdominal wall and upper thighs. Outpatient follow-up occurred at 2 weeks and months 1, 2, 3, 4, 5, and 6 after initiation of therapy. During follow-up, a CXR, complete pulmonary function studies, a 6-min walk test, a dyspnea questionnaire, and a Short Form-36 (SF-36) quality of life questionnaire were obtained. A CBC with differential was obtained on a weekly
Parameters for Study Discontinuation
The study was discontinued if patients had one of the following: (1) progression of the underlying PAP leading to deterioration of the respiratory status requiring hospitalization for WLL (assessed based on symptoms, physical examination, CXR, and oxygenation); (2) serious allergic or anaphylactic reaction with the first dose of GM-CSF or during subsequent therapy; (3) persistent significant laboratory abnormalities including, but not limited to, WBC count > 50,000/μL, absolute neutrophil count
Study Outcomes
The primary end point was an improvement in oxygenation as assessed by a ≥ 10 mm Hg decrease in the room air alveolar-arterial oxygen gradient (P[A-a]O2). For the patients who received GM-CSF therapy after hospital admission for bilateral lavage (history of two or more WLLs in the prior 4 months), the primary outcome variable was the need for subsequent therapeutic lavage or further hospital admission days (rather than oxygenation). Secondary end points were as follows: (1) improvement in
Radiographic Grading
Single frontal CXRs were graded as to the presence and extent of lung opacification using a visual scoring system similar to one described by Remy-Jardin et al.17 Scores were determined for degree of opacification, extent of opacification, and severity of opacification.
The CXRs (n = 21) were interpreted blindly by our radiologist (M.M.), without the knowledge of clinical, laboratory, or pulmonary function test results, or whether the radiographs were before or after treatment. The presence and
Statistical Analysis
The two groups were compared on the normally distributed variables using Student t test and on the nonnormally distributed variables using Wilcoxon rank-sum test. The responders and nonresponders were compared on the difference between follow-up and baseline variables of interest (Pao2, P(A-a)O2, diffusing capacity, total lung diffusion capacity/alveolar volume, total lung capacity, FVC, 6-min walk distance, WBC count, lactate dehydrogenase [LDH], and the duration and maximum dose of therapy).
Results
Twenty-seven patients with adult idiopathic PAP were screened, and 25 patients were enrolled in the trial. Figure 1is a flow chart showing the disposition of all screened patients. Circulating anti–GM-CSF antibodies were present in all patients, measured in pretreatment sera as previously described. Among the 25 patients enrolled in the trial, 18 were men and 7 were women. The demographics and baseline characteristics are shown in Table 1. Of the 25 patients enrolled, 4 patients did not
Long-term Follow-up
The patients were followed up for a mean (± SD) duration of 39 ± 17.3 months. Of the 12 responders, 8 patients (67%) did not require WLL or home oxygen, and 4 patients (33%) required WLL for a mean of two occasions (range, one to five occasions). Of the nine nonresponders, four patients (44%) did not require WLL or home oxygen, and five patients (56%) required WLL once. Of four others screened initially, three required WLL.
Toxicity
Overall, the drug was well tolerated. Table 5lists the adverse events noted in the study participants. The majority of the side effects were minor and included injection-site edema, erythema, and malaise. Shortness of breath was noted in 10 patients. It is unclear whether the shortness of breath was related to PAP or the GM-CSF therapy. There were no bone marrow or lung toxicities.
Discussion
The primary finding from this open-label study was that administration of GM-CSF improved oxygenation as assessed by a decrease in P(A-a)O2 as well as other clinical variables in 12 of 25 adult patients (48%) with idiopathic PAP with moderately symptomatic disease. Response to GM-CSF conferred a meaningful benefit clinically to the patients with PAP, with improvements in symptomatology (both dyspnea as well as overall quality of life), reduction in supplemental oxygen requirement, frequency of
References (23)
- et al.
Pulmonary alveolar proteinosis: progress in the first 44 years
Am J Respir Crit Care Med
(2002) The benefits of whole lung lavage in pulmonary alveolar proteinosis
Eur Respir J
(2004)- et al.
Persistence of pulmonary pathology and abnormal lung function in IL-3/GM-CSF/IL-5 β c receptor-deficient mice despite correction of alveolar proteinosis after BMT
Bone Marrow Transplant
(1997) - et al.
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis
Science
(1994) - et al.
Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice
J Clin Invest
(1996) - et al.
The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 beta c receptor-deficient mice is reversed by bone marrow transplantation
J Exp Med
(1996) - et al.
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology
Proc Natl Acad Sci U S A
(1994) - et al.
Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect
Clin Immunol
(2000) - et al.
Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor
J Exp Med
(1999) - et al.
Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis
N Engl J Med
(1996)
Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis
Am J Respir Crit Care Med
Cited by (126)
Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression
2022, Molecular Therapy Methods and Clinical DevelopmentIntroduction on Treatment for Infectious Diseases and Immunological Disorders
2022, Encyclopedia of Infection and ImmunityPulmonary Alveolar Proteinosis
2021, Encyclopedia of Respiratory Medicine, Second Edition
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
Dr. Venkateshiah is presently at Creighton University, Omaha, NE.
This study was supported by a research grant from Berlex, formerly Immunex Corporation, Seattle, WA.